Legal status · United States
Is Amylin legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Amylin is not an approved medicine in the United States; its classification is "Not a drug; endogenous hormone and research infusion peptide". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 2 human studies are cited on its profile.
Amylin in the United States at a glance
| Classification | Not a drug; endogenous hormone and research infusion peptide |
|---|---|
| Note | Drugs acting at its receptor are approved. The hormone itself is not a therapeutic. |
| FDA approval status | Native amylin is not a drug. Its approved analogue pramlintide (Symlin) is listed as Discontinued in Drugs@FDA as of September 2026. Cagrilintide is investigational, in phase 3 combined with semaglutide. |
| Human studies cited | 2 of 3 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Amylin profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
No product containing Amylin is approved by FDA for any use in the United States, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in the United States. This page is general information, not legal advice.
What Amylin is
Co-released with insulin from the same beta cell, and the parent ligand of cagrilintide and CagriSema. Native human amylin clumps into amyloid, which is why it can never be a drug.
Amylin is secreted alongside insulin from the pancreatic beta cell in a roughly fixed ratio, which has a consequence people miss: someone with type 1 diabetes is deficient in two hormones, not one. It slows gastric emptying, suppresses glucagon after a meal, and produces satiation through the area postrema in the brainstem.
Mechanism: Acts at amylin receptors, which are not dedicated receptors at all but the calcitonin receptor in complex with a receptor activity-modifying protein. RAMP1, RAMP2 or RAMP3 give AMY1, AMY2 and AMY3 respectively, and that accessory-protein mechanism is why amylin pharmacology overlaps with calcitonin.
Regulatory history: Native amylin is not a drug. Its approved analogue pramlintide (Symlin) is listed as Discontinued in Drugs@FDA as of September 2026. Cagrilintide is investigational, in phase 3 combined with semaglutide.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Amylin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Amylin in other countries
Frequently asked questions
Is Amylin legal in the United States?
No. Amylin is not an approved medicine in the United States; its classification is "Not a drug; endogenous hormone and research infusion peptide". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 2 human studies are cited on its profile. Note: Drugs acting at its receptor are approved. The hormone itself is not a therapeutic.
Can I buy Amylin in the United States?
No approved product exists to buy. In the United States Amylin is classified as "Not a drug; endogenous hormone and research infusion peptide", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Drugs acting at its receptor are approved. The hormone itself is not a therapeutic.
Is Amylin FDA approved?
No. FDA status: Native amylin is not a drug. Its approved analogue pramlintide (Symlin) is listed as Discontinued in Drugs@FDA as of September 2026. Cagrilintide is investigational, in phase 3 combined with semaglutide.. Current US classification: "Not a drug; endogenous hormone and research infusion peptide". On the evidence, 2 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Amylin live on its compound profile.
Amylin profileThis page is general information about the regulatory status of Amylin in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.